AstraZeneca Advances Selumetinib - Analyst Blog

By
A A A

AstraZeneca ( AZN ) has initiated a phase III program for its oncology candidate, selumetinib. The company is looking to get selumetinib approved as second-line treatment in patients, who suffer from advanced or metastatic non-small-cell lung cancer (NSCLC) with KRAS mutation-positive tumors.

The SELECT-1 (SELumetinib Evaluation as Combination Therapy-1) study aims to enroll 634 NSCLC patients to compare the safety and efficacy of selumetinib in combination with Sanofi 's ( SNY ) Taxotere (docetaxel) to Taxotere and placebo. Results will be measured on the basis of progression free survival (PFS) and overall survival.

AstraZeneca advanced selumetinib into phase III studies on the basis of encouraging data from a randomized phase II study, Study 16, evaluating selumetinib plus Taxotere versus Taxotere alone in KRAS-mutation positive NSCLC. Statistically significant PFS was observed in the selumetinib plus Taxotere arm (5.3 months) as compared to Taxotere alone (2.1 months).

We remind investors that in 2003, AstraZeneca acquired exclusive worldwide rights to selumetinib from Array BioPharma ( ARRY ).

Generic competition has been adversely impacting AstraZeneca's revenues over the past few quarters. This has put significant pressure on the company.

In a bid to add late-stage candidates to its pipeline, AstraZeneca entered into a number of acquisition deals (Pearl Therapeutics and Omthera Pharmaceuticals) in the last few months and agreements with companies such as FibroGen, Inc.

AstraZeneca, a large-cap pharma company, presently carries a Zacks Rank #3 (Hold). Other large-cap pharma stocks such as Roche ( RHHBY ) looks well positioned with a Zacks Rank #1 (Strong Buy).



ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Get Free Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ARRY , AZN , PFS , RHHBY , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

How to Fire Your Adviser
How to Fire Your Adviser            

Stocks

Referenced

Most Active by Volume

75,750,465
  • $16.77 ▲ 0.36%
59,791,764
  • $101.58 ▲ 0.71%
38,720,622
  • $42.59 ▼ 0.28%
37,416,417
  • $46.52 ▼ 0.51%
35,101,793
  • $16.28 ▲ 0.74%
34,987,975
  • $99.53 ▲ 0.15%
33,760,830
  • $3.63 ▲ 0.69%
32,148,671
  • $17.61 ▲ 0.57%
As of 9/17/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com